PO.CL05.09 · 临床研究

KLRC2缺失在种族多样的前列腺癌患者中的遗传学表征

Genetic characterization of KLRC2 deletion in racially diverse prostate cancer patients

海报缩略图:KLRC2缺失在种族多样的前列腺癌患者中的遗传学表征
编号 6583 展板 16 时间 4/21 02:00–05:00 区域 Section 45 主讲 Laila Scroggins, BS
分会场 Inflammation, Immunity, and Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Laila Scroggins, Paula O. Cooper, Stefan DiFazio, Kun-Lin Ho, Sally Elsamanoudi, Jiji Jiang, Shyh-Han Tan, Ayesha A. Shafi, Cara C. Schafer

Surgery, Center for Prostate Disease Research, Bethesda, MD

摘要 Abstract

中文摘要
自然杀伤(NK)细胞通过直接裂解肿瘤细胞成为抗肿瘤免疫的关键介导者。新出现的证据表明,非裔美国人(AA)和白人美国人(CA)男性的前列腺肿瘤在免疫微环境方面存在显著差异;然而,NK细胞相关基因对这些差异的贡献仍未被充分理解。NK细胞受体基因KLRC2尤其受关注,因为我们患者队列中的既往研究表明,与CA肿瘤相比,AA前列腺肿瘤中KLRC2表达显著更低。鉴于种系KLRC2缺失多态性在全球人群中有所不同,包括具有东非和西非血统的人群,研究其缺失状态可能为下游表达差异及相关免疫变异提供见解。本研究旨在通过在种族多样的基因组数据集中评估一个与NK细胞相关的基因KLRC2,来更深入地理解AA和CA前列腺癌(PCa)男性之间的免疫生物学差异。我们假设种系缺失可能导致其在肿瘤组织中下游表达的变异性,并最终导致所观察到的PCa种族差异。理解种系缺失变异可能为驱动肿瘤免疫微环境差异的机制以及减少PCa结局中这些差异的策略提供见解。我们分析了来自一个大型前列腺疾病研究中心(CPDR)队列的种系全基因组测序数据,包括非裔美国人(AA,n=259)和白人美国人(CA,n=272)男性。应用生物信息学工作流程准确推断KLRC2缺失状态,包括拷贝数判定和质量控制过滤。我们在这个稳健的CPDR队列中发现AA和CA男性之间KLRC2杂合缺失状态存在显著差异。这些发现提示KLRC2拷贝数存在群体水平的变异,这可能解释了此前在AA前列腺肿瘤中观察到的KLRC2表达降低。种系KLRC2缺失可能影响前列腺肿瘤微环境内NK细胞介导的活性,尤其是在非裔美国人男性中。我们的发现提供了基础性证据,表明KLRC2状态可能在种族免疫差异中发挥作用。这些发现将KLRC2定位为一个有前景的生物标志物以及基于NK细胞的免疫治疗策略的潜在候选靶点。本出版物的内容完全由作者负责,不一定反映美国军队卫生服务大学(USUHS)、亨利·M·杰克逊军事医学促进基金会、战争部(DoW)或陆军、海军或空军各部门的观点、意见或政策。提及商品名、商业产品或组织并不意味着美国政府对其认可。
查看英文原文 English abstract
Natural Killer (NK) cells are key mediators of anti-tumor immunity through direct tumor cell lysis. Emerging evidence suggests significant immune microenvironment differences in prostate tumors between African American (AA) and Caucasian American (CA) men; however, the contribution of NK cell-associated genes to these disparities remains incompletely understood. The NK cell receptor gene KLRC2 is of particular interest because prior research within our patient cohort demonstrated significantly lower KLRC2 expression in AA prostate tumors compared to CA tumors. Given that germline KLRC2 deletion polymorphisms differ across global populations, including those with East and West African ancestry, investigating its deletion status may provide insight into downstream expression differences and associated immune variation. This study aims to gain a deeper understanding of immunobiological differences between AA and CA men with prostate cancer (PCa) by evaluating an NK cell-relevant gene, KLRC2 , in racially diverse genomic datasets. We hypothesized that germline deletion may contribute to its variability in downstream expression in tumor tissues and ultimately contribute to observed racial disparities in PCa. Understanding germline deletion variations may provide insight into mechanisms driving tumor immune microenvironment differences and strategies to reduce these disparities in PCa outcomes. We analyzed germline, whole genome sequencing data from a large Center for Prostate Disease Research (CPDR) cohort including African American (AA, n=259) and Caucasian American (CA, n=272) men. Bioinformatics workflows were applied to accurately infer KLRC2 deletion status, including copy-number calling and quality control filtering. We identified a significant difference in the heterozygous deletion status of KLRC2 between AA and CA men in this robust CPDR cohort. These findings suggest population-level variation in KLRC2 copy number that may account for reduced KLRC2 expression previously observed in AA prostate tumors. Germline KLRC2 deletions may influence NK cell-mediated activity within the prostate tumor microenvironment, particularly among African America men. Our findings provide foundational evidence that KLRC2 status may play a role in racial immune disparities. These findings place KLRC2 as a promising biomarker and potential candidate for NK cell-based immunotherapeutic strategies. The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions or policies of Uniformed Services University of the Health Sciences (USUHS), the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of War (DoW) or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.
利益披露 Disclosure
L. Scroggins, None.. P. O. Cooper, None.. S. DiFazio, None.. K. Ho, None.. S. Elsamanoudi, None.. J. Jiang, None.. S. Tan, None.. A. A. Shafi, None.. C. C. Schafer, None.

← 返回 AACR 2026 检索